Biogen Halves Aduhelm Price, Readies $500m In Cost Cuts
Potential Job Losses Loom As Holidays Approach
Executive Summary
The Alzheimer’s drug’s price was cut to $28,200 per year just one month before CMS is expected to issue a draft national coverage determination for amyloid-clearing antibodies, raising questions about the timing.
You may also be interested in...
How Biogen’s Aduhelm Bet Became A Commercial Bust
Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later.
How Biogen’s Aduhelm Bet Became A Commercial Bust
Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later.
CEO Vounatsos, Aduhelm Commercial Team To Exit As Biogen Shifts Focus
The company will prioritize later-stage R&D, including potential accelerated approval for a second anti-amyloid antibody, while replacing its CEO and cutting Aduhelm commercial operations and other costs.